Arsenic Trioxide Targets miR-125b in Glioma Cells

Author(s): Sulian Chen, Lihua Zhu, Jing Huang, Ying Cai, Xiaohui Lu, Qingling Yang, Qiong Wu, Changjie Chen, Zhiwei Wang

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 33 , 2014

Become EABM
Become Reviewer


Background: Arsenic trioxide (As2O3) has been demonstrated to suppress tumorigenesis in human glioma. However, the exact molecular mechanisms by which As2O3 exerts its tumor suppressor functions are elusive. Therefore, it is warranted to explore the underlying mechanism of As2O3–mediated anti-tumor activity in glioma.

Methods: To achieve our goal, we used multiple approaches including MTT assay, apoptosis, Real-time RT-PCR, Western blotting, invasion assay, and gene transfection.

Results: We observed that A22O3 inhibited cell growth and induced apoptosis as well as suppressed migration and invasion in human glioma cells. Moreover, we found that As2O3 down-regulated miR-125b expression and subsequently up-regulated its target gene Bak1 expression. Furthermore, we identified that As2O3 exerts its anti-tumor activity partly through regulation of miR-125b.

Conclusions: Our present study suggests that As2O3 could be a potential therapeutic agent for treatment of human glioma.

Keywords: As2O3, glioma, invasion, miR-125b, Bak1.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 10 September, 2014
Page: [5354 - 5361]
Pages: 8
DOI: 10.2174/1381612820666140128204132
Price: $65

Article Metrics

PDF: 34